Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada

References

• Health Canada. A report on mental illnesses in Canada. Ottawa, Canada: Health Canada, 2002
   Google Scholar
• Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005;21:2017-28
   PubMed Web of Science ®Google Scholar
• Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009;373:4-5
   PubMed Web of Science ®Google Scholar
• Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophrenia Bull 2009;35:931-6
   PubMed Web of Science ®Google Scholar
• Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr Dis Treat 2009;5:483-90
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7
   PubMed Web of Science ®Google Scholar
• Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PloS One 2013;8:e81208
   PubMed Web of Science ®Google Scholar
• van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45
   PubMed Web of Science ®Google Scholar
• Yevtushenko OO, Cooper SJ, O'Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008;192:424-8
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-9
   PubMed Web of Science ®Google Scholar
• Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010;71(2 Suppl):20-6
   PubMedGoogle Scholar
• Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65(18 Suppl):13-26
   PubMedGoogle Scholar
• Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62(7 Suppl):32-7
   PubMedGoogle Scholar
• Wong MM, Chen EY, Lui SS, et al. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin Schizophr Relat Psychoses 2011;5:135-41
   PubMedGoogle Scholar
• McIntyre RS, Cragin L, Sorensen S, et al. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract 2010;16:744-55
   PubMed Web of Science ®Google Scholar
• Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2011;124:214–25
   PubMed Web of Science ®Google Scholar
• Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010;43:138-46
   PubMed Web of Science ®Google Scholar
• Bloom D, Iskandar H. Psychiatrists. [Consulted August 2011]. Montreal, Quebec: Douglas Mental Health University Institute
   Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63:1762-84
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-60
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-22
   PubMed Web of Science ®Google Scholar
• National Institute for Health & Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adult in primary and secondary care (Updated edition). National Clinical Guideline Number 82. London: National Collaborating Centre for Mental Health, 2010
   Google Scholar
• Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009;14:429-47
   PubMed Web of Science ®Google Scholar
• Szegedi A, Verweij P, van Duijnhoven W, et al. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry 2012;73:1533-40
   PubMed Web of Science ®Google Scholar
• Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011;72:349-55
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Consumer Price Index, Health Care: CANSIM Table 326-0020. 2011
   Google Scholar
• Régie de l'assurance maladie du Québec. Liste de médicaments. 33e édition. Quebec, Canada, 2011
   Google Scholar
• Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005;50(13 Suppl 1):7S-57S
   Google Scholar
• Public Health Agency of Canada. Tracking heart disease and stroke in Canada. Cat HP32-3/2009E, Ottawa, Canada, 2009
   Google Scholar
• Public Health Agency of Canada. Report from the Canadian Chronic Disease Surveillance System: Hypertension in Canada, 2010. Chronic Disease Surveillance Division, ed. Ottawa: Public Health Agency of Canada 2010
   Google Scholar
• Patra J, Popova S, Rhem J, et al. Economic cost of chronic disease in Canada: 1995–2003. Prepared for the Ontario Chronic Disease Prevention Alliance and the Ontario Public Health Association. 2007
   Google Scholar
• Heart and Stroke Foundation of Canada. The growing burden of heart disease and stroke in Canada. Vol 1-896242-30-8. Ottawa, Canada: Heart and Stroke Foundation of Canada, 2003
   Google Scholar
• Public Health Agency of Canada. Diabetes in Canada: highlights from the National Diabetes Surveillance System 2004 – 2005. Ottawa: Public Health Agency of Canada, 2008
   Google Scholar
• Wilkins K, Park E. Home care in Canada. Health Rep 1998;10:29–37(ENG);31–40(FRE)
   Google Scholar
• Goeree R, Blackhouse R, Petrovic R, et al. Cost of stroke in Canada: a 1-year prospective study. J Med Econ 2005;8:147-67
   Google Scholar
• Schultz SE, Kopec JA. Impact of chronic conditions. Health Rep 2003;14:41-53
   PubMedGoogle Scholar
• Statistics Canada. Life Tables, Canada, provinces and territories, 2000-2002 (Catalogue no. 84-537-XIE). Ottawa: Minister of Industry E, 2006
   Google Scholar
• Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-8
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Death and mortality rates, by selected groupes causes, age, group and sex, Table 102-0551 (Catalogue no. 84F0209X). Ottowa: Minister of Industry, 2007
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;(3):CD006654
   Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bull 2012;38:167-77
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225-33
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
   PubMed Web of Science ®Google Scholar
• Potkin SG, Phiri P, Szegedi A, et al. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res 2013;150:442-9
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21
   PubMed Web of Science ®Google Scholar
• Oguma Y, Sesso HD, Paffenbarger RS, Jr., et al. Weight change and risk of developing type 2 diabetes. Obes Res 2005;13:945-51
   PubMedGoogle Scholar
• Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6
   PubMed Web of Science ®Google Scholar
• Williams PT. Increases in weight and body size increase the odds for hypertension during 7 years of follow-up. Obesity (Silver Spring) 2008;16:2541-8
   PubMedGoogle Scholar
• Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998;128:81-8
   PubMed Web of Science ®Google Scholar
• Galanis DJ, Harris T, Sharp DS, et al. Relative weight, weight change, and risk of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol 1998;147:379-86
   PubMed Web of Science ®Google Scholar
• Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal' weight range. JAMA 1995;273:461-5
   PubMed Web of Science ®Google Scholar
• Asplund K, Karvanen J, Giampaoli S, et al. Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke 2009;40:2319-26
   PubMed Web of Science ®Google Scholar
• Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 2005;28:1339-45
   PubMed Web of Science ®Google Scholar
• Lotufo PA, Gaziano JM, Chae CU, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001;161:242-7
   PubMed Web of Science ®Google Scholar
• Biagini E, Elhendy A, Schinkel AF, et al. Comparison of all-cause mortality in women with known or suspected coronary artery disease referred for dobutamine stress echocardiography with normal versus abnormal test results. Am J Cardiol 2005;95:1072-5
   PubMedGoogle Scholar
• Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001;32:2131-6
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65
   PubMed Web of Science ®Google Scholar
• Régie de l’assurance maladie du Québec. Manuel des médecins spécialistes. Quebec, Canada, 2011
   Google Scholar